<DOC>
	<DOCNO>NCT03075670</DOCNO>
	<brief_summary>This trial conduct Europe United States America . The aim trial compare pharmacokinetics ( exposure trial drug body ) nonacog beta pegol ( N9-GP ) ALPROLIX® patient haemophilia B .</brief_summary>
	<brief_title>A Trial Comparing Nonacog Beta Pegol ( N9-GP ) ALPROLIX® Patients With Haemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Male , age 1870 year ( inclusive ) time sign informed consent Patients diagnosis congenital haemophilia B factor IX activity equal 2 % , base medical record History 150 exposure day factor IX containing product Known history factor IX inhibitor Inhibitors factor IX ( equal 0.6 BU ) screening measure Nijmegen modify Bethesda method Immunocompromised ( CD4+ T cell equal 200/μL ) Known congenital acquire coagulation disorder haemophilia B Body mass index 35 kg/m^²</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>